Benzinga | Apr 30, 2021 09:22AM EDT

Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $455

Canaccord Genuity analyst Kyle Rose maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $445 to $455.